Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.

By Robert Izquierdo – Apr 13, 2026 at 10:24AM ESTKey PointsCEO Berndt Modig sold 23,333 shares on April 9, 2026, generating a transaction value of ~$647,000 at a weighted average price of around $27.74 per share.The sale represented 2.09% of Modig's total Pharvaris holdings at the time of the transaction.No indirect shares were traded; 950,000 shares remain held indirectly via Schoodif Management BV, with direct post-transaction holdings at 142,084 shares.On April 9, 2026, Berndt Modig, Chief Executive Officer of Pharvaris N.V. (PHVS +1.48%), reported the direct sale of 23,333 common shares for a total transaction value of approximately $647,000, according to a SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)23,333Transaction value~$647,000Post-transaction shares (direct)142,084Post-transaction shares (indirect)950,000Post-transaction value (direct ownership)~$3.85 millionTransaction value based on SEC Form 4 weighted average purchase price ($27.74); post-transaction value based on April 9, 2026 market close (using $27.07 per share).Key questionsWhat portion of Modig's stake was affected by this transaction?This sale accounted for 14.11% of Modig's direct position but only 2.09% of his total Pharvaris holdings, given the substantial indirect stake retained through Schoodif Management BV.Did the transaction involve any derivative securities or indirect holdings?No derivative securities or indirect shares were transacted; all 23,333 shares sold were held directly prior to the disposition.How does this activity fit within the context of Modig's recent trading and available capacity?With direct holdings reduced to 142,084 shares post-sale and indirect holdings unchanged, the transaction reflects routine Rule 10b5-1 liquidity management and a shrinking available direct share base for further sales.How does the sale price compare to recent market levels?The weighted average sale price of around $27.74 per share was slightly above the latest closing price of $26.63 as of April 10, 2026.Company overviewMetricValuePrice (as of market close 2026-04-09)$27.07Market capitalization$1.74 billionNet income (TTM)($175.70 million)1-year price change121.92%* 1-year performance calculated using April 9th, 2026 as the reference date.Company snapshotPharvaris N.V. develops oral therapies targeting hereditary angioedema (HAE), including PHA121, PHVS416 (on-demand soft capsule), and PHVS719 (prophylactic extended-release tablet), with products in various phases of clinical trials.The company operates a clinical-stage biopharmaceutical model, focusing on research, development, and future commercialization of proprietary small-molecule drugs for rare diseases.Pharvaris N.V. is a Leiden-based biotechnology company specializing in the development of oral therapies for rare diseases, with a primary focus on hereditary angioedema.The company leverages its expertise in small-molecule drug discovery to advance a pipeline of differentiated treatments targeting significant unmet medical needs. Its strategy centers on clinical innovation and global market access to establish a competitive position in the rare disease therapeutics landscape.What this transaction means for investorsPharvaris CEO Berndt Modig’s April 9 sale of 23,333 company shares was executed as part of his Rule 10b5-1 trading plan. Such a plan is often implemented by insiders to avoid accusations of making trades based on insider information.Consequently, the transaction isn’t a red flag for investors. Modig also holds over 900,000 shares indirectly, suggesting that he is not in a rush to dispose of his holdings.Pharvaris stock is up in 2026, reaching a 52-week high of $29.85 on April 1, thanks to encouraging results in its clinical trials. The company produces no revenue yet, and it exited 2025 with a net loss of 176 million euros.However, at the end of 2025, it held cash and equivalents of 292 million euros, up from the prior year’s 281 million euros. This provides funds to maintain operations for a time.The question is whether Pharvaris can eventually attain government approval for its treatments. Any investment in the company is a risk at this point, and the prudent approach is to wait until those approvals are secured before deciding to invest. But for shareholders, now may be a good time to sell, considering the rise in share price this year.Read NextApr 13, 2026 •By Sarah SidlowSlide's Chief Risk Officer Just Dumped All of His Shares, Again.

What Does It Mean for Insurance Investors?Apr 13, 2026 •By Sarah SidlowHagerty Director Sells 5,531 Shares for $61,000Apr 13, 2026 •By Jake LerchWealth Manager Sheds $5.3 Million Worth of Data Center ETF, According to Latest SEC FilingApr 13, 2026 •By Sarah Sidlow10% Owner Control Empresarial Has Been Dumping PBF Energy This Year.

What Does It Mean for Individual Investors?Apr 13, 2026 •By Pamela KockInsider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)Apr 12, 2026 •By Eric TrieElmwood Wealth Management Adds to Goldman Sachs S&P 500 Premium Income ETF, According to Recent SEC FilingAbout the AuthorRobert "Izzy" Izquierdo is a contributing Motley Fool stock market analyst covering information technology, consumer discretionary, consumer staples, and communication services sectors. Prior to The Motley Fool, Izzy was head of product management at Target Media Partners, developing and launching multimillion-dollar software used by businesses such as Charter Communications. Prior to that, he worked at Yahoo! and startups on software products in connected TV, AI, consumer apps, and digital advertising. He holds a bachelor’s degree in English literature from UCLA and is certified in software product management.TMFWryWriteStocks MentionedPharvarisNASDAQ: PHVS$27.03(+1.48%)+$0.40*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.